Stent thrombosis relationship to discontinuation of antiplatelet therapy

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search

WikiDoc Resources for

Stent thrombosis relationship to discontinuation of antiplatelet therapy

Articles

Most recent articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Most cited articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Review articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Articles on Stent thrombosis relationship to discontinuation of antiplatelet therapy in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Images of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Photos of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Podcasts & MP3s on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Videos on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Evidence Based Medicine

Cochrane Collaboration on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Bandolier on Stent thrombosis relationship to discontinuation of antiplatelet therapy

TRIP on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Clinical Trials

Ongoing Trials on Stent thrombosis relationship to discontinuation of antiplatelet therapy at Clinical Trials.gov

Trial results on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Clinical Trials on Stent thrombosis relationship to discontinuation of antiplatelet therapy at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Stent thrombosis relationship to discontinuation of antiplatelet therapy

NICE Guidance on Stent thrombosis relationship to discontinuation of antiplatelet therapy

NHS PRODIGY Guidance

FDA on Stent thrombosis relationship to discontinuation of antiplatelet therapy

CDC on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Books

Books on Stent thrombosis relationship to discontinuation of antiplatelet therapy

News

Stent thrombosis relationship to discontinuation of antiplatelet therapy in the news

Be alerted to news on Stent thrombosis relationship to discontinuation of antiplatelet therapy

News trends on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Commentary

Blogs on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Definitions

Definitions of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Patient Resources / Community

Patient resources on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Discussion groups on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Patient Handouts on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Directions to Hospitals Treating Stent thrombosis relationship to discontinuation of antiplatelet therapy

Risk calculators and risk factors for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Healthcare Provider Resources

Symptoms of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Causes & Risk Factors for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Diagnostic studies for Stent thrombosis relationship to discontinuation of antiplatelet therapy

Treatment of Stent thrombosis relationship to discontinuation of antiplatelet therapy

Continuing Medical Education (CME)

CME Programs on Stent thrombosis relationship to discontinuation of antiplatelet therapy

International

Stent thrombosis relationship to discontinuation of antiplatelet therapy en Espanol

Stent thrombosis relationship to discontinuation of antiplatelet therapy en Francais

Businness

Stent thrombosis relationship to discontinuation of antiplatelet therapy in the Marketplace

Patents on Stent thrombosis relationship to discontinuation of antiplatelet therapy

Experimental / Informatics

List of terms related to Stent thrombosis relationship to discontinuation of antiplatelet therapy

Cardiology Network

Discuss Stent thrombosis relationship to discontinuation of antiplatelet therapy further in the WikiDoc Cardiology Network
Adult Congenital
Biomarkers
Cardiac Rehabilitation
Congestive Heart Failure
CT Angiography
Echocardiography
Electrophysiology
Cardiology General
Genetics
Health Economics
Hypertension
Interventional Cardiology
MRI
Nuclear Cardiology
Peripheral Arterial Disease
Prevention
Public Policy
Pulmonary Embolism
Stable Angina
Valvular Heart Disease
Vascular Medicine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Incidence of stent thrombosis (ST) of drug eluting stents (DES) in relation to antiplatelet medication use

Incidence of ST on dual antiplatelet therapy.

In a prospective study of 2229 patients with DES 83% ST occurred in patients who were on dual antiplatelet therapy. ref1.

Incidence of early ST while on dual antiplatelet therapy

  • This category would include incidence of acute and subacute ST

In a study of 1911 patients on dual antiplatelet therapy a ST rate of 0.05% was reported. (one patient) ref2.

In the real world setting in an observational study involving 15157 patients with SES rate of acute ST was 0.13%. ref3.

A rate of 0.15 % subacute ST was reported in a study of 1911 patients who were treated with aspirin, clopidogrel and on the treating physicians discretion - GP2b3a ref1.

Incidence of late ST while on dual antiplatelet therapy

  • This category would include incidence of late and very late ST

In a cohort of 2006 patients with PES and SES up to a mean follow-up of 15 months with a follow up rate of 98% of the patients, no ST occurred while patients were on dual antiplatelet therapy ref4.

A study involving 1911 patients who had DES, showed a (??late) incidence of 0.2% of ST while on dual antiplatelet therapy ref2.

Incidence of ST of DES while on single antiplatelet therapy.

Incidence of early ST of DES while on single antiplatelet therapy.

  • This category would include acute and subacute ST while on single antiplatelet therapy.
  • This is an uncommon category as most patients are on dual antiplatelet medications.
    • How ever it has been suggested that those patients who are suboptimally loaded with dual antiplatelet therapy and who also receive bivalirudin, may be at an increased risk of ST during the waning of the effect of bivalirudin and until dual antiplatelet effects becomes adequate.
    • Another scenario is the patient who is intolerant to one antiplatelet medication. This again is a very uncommon situation, as hospitals use aspirin desensitization and clopidogrel desensitization.

Incidence of late ST of DES while on single antiplatelet therapy

  • This category would include late ST and very late ST

Overall the incidence of late ST in patients who presented on aspirin monotherapy was 0.25%. How ever no data was reported as to the proportion of patients who were on aspirin monotherpay at that time. 60% of the patients who presented with late ST and were on aspirin monotherpay after 6 months of the procedure. It is possible that the majority of the patients may have been on aspirin monotherapy at that time, yielding an incidence of ST for this group of 0.25% ref1.

In a study involving 1911 patients who had DES 0.15% of patients who presented with late ST were on one antiplatelet therapy. How ever it is not clear as to the number of patients in the whole cohort who were on single antiplatelet therapy ref1. In one study, hazard ratio for late ST on premature discontinuation of antiplatelet therapy was 57.13 (14.84 - 219.96) ref1.

Incidence of ST of DES while on no antiplatelet therapy

Incidence of early ST while on no antiplatelet therapy

This is an unlikely scenario in the current environment.

Incidence of late ST while on no antiplatelet therapy

On long term follow up to 19.4 months, 121 patients with DES had complete interruption of antiplatelet therapy with a ST rate of 3.3 % in that group. (this represented an overall risk of 0.2 % when applied to the whole study population.) In the same group the rate of ST when both antiplatelet therapies were stopped within 6 months of stent implantation was 9%. ref2.

Two patients presented with ST who were 343 and 335 days following DES implantation. They had ceased dual antiplatelet therapy within 14 days of ST . Data of other patients who had a DES with no antiplatelet cover for the same duration was not available. ref5.

One patient had ST following discontinuation of both antiplatelet medications. ? DES or BMS ? late or very late?( awaiting further information) ref6.

Back to main page Coronary stent thrombosis

References

  1. Ref1 Iakovou, I, Schmidt, T, Bonizzoni, E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005; 293:2126
  2. Ref2 Park DW, Park SW, Park KH, Lee BK, Kim YH, Lee CW, Hong MK, Kim JJ, Park SJ. Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up. Am J Cardiol. 2006;98:352–356.
  3. Ref3 Urban, P, Gershlick, AH, Guagliumi, G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006; 113:1434.
  4. Ref4 Ong, AT, McFadden, EP, Regar, E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088
  5. Ref5 McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler nLF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364: 1519–1521.
  6. Ref6 Wilson SH; Fasseas P; Orford JL; Lennon RJ; Horlocker T; Charnoff NE; Melby S; Berger PB Clinical outcome of patients undergoing non-cardiac surgery in the two months following coronary stenting. J Am Coll Cardiol 2003 Jul 16;42(2):234-40
WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

Personal tools